Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang’s Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024

2020 ◽  
Author(s):  
Konrad H. Stopsack
Keyword(s):  
Prostate Cancer ◽  
Dna Repair ◽  
Parp Inhibition ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Castration Resistant ◽  
Letter To The Editor

Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial

The Lancet ◽  
2021 ◽  
Vol 398 (10295) ◽  
pp. 131-142
Author(s):  
Christopher Sweeney ◽  
Sergio Bracarda ◽  
Cora N Sternberg ◽  
Kim N Chi ◽  
David Olmos ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Double Blind ◽  
Castration Resistant

scholarly journals Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study

2017 ◽  
Vol 71 (2) ◽  
pp. 151-154 ◽  
Author(s):  
Tomasz M. Beer ◽  
Andrew J. Armstrong ◽  
Dana Rathkopf ◽  
Yohann Loriot ◽  
Cora N. Sternberg ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Castration Resistant ◽  
Extended Analysis

scholarly journals Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint

2019 ◽  
Vol 75 (6) ◽  
pp. 929-937 ◽  
Author(s):  
Ethan M. Basch ◽  
Mark Scholz ◽  
Johann S. de Bono ◽  
Nicholas Vogelzang ◽  
Paul de Souza ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Castration Resistant Prostate Cancer ◽  
Phase 3 ◽  
Castration Resistant
Sign in / Sign up

Export Citation Format

Share Document